This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

NCT07520318 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Adults With Neovascular Age-related Macular Degeneration

Interventions

DRUG: bispecific anti-VEGF and anti-complement

Sponsor

Shenzhen Oculgen Biomedical Technology Co., Ltd.